Literature DB >> 1156509

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.

M V Pimm, R W Baldwin.   

Abstract

ICRF 159 and Triton WR 1339 have been examined for their ability to suppress subcutaneous growth and pulmonary metastases from a transplanted rat epithelioma. Neither compound influenced subcutaneous tumour development or reduced the propensity to metastasize when administered in regimens reported to suppress pulmonary, lymph node or intracerebral metastases in other experimental system.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1156509      PMCID： PMC2009359          DOI： 10.1038/bjc.1975.7

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  11 in total

1.  Accurate identification of experimental pulmonary metastases.

Authors:  H Wexler
Journal:  J Natl Cancer Inst       Date:  1966-04       Impact factor: 13.506

2.  BGG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin.

Authors:  R W Baldwin; M V Pimm
Journal:  Int J Cancer       Date:  1973-09-15       Impact factor: 7.396

3.  Selective chemotherapy of cancer metastases with triton WR 1339.

Authors:  G Franchi; S Garattini
Journal:  Eur J Cancer       Date:  1971-12       Impact factor: 9.162

4.  Control of malignant metastases by ICRF l59.

Authors:  K Hellmann; K Burrage
Journal:  Nature       Date:  1969-10-18       Impact factor: 49.962

5.  Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic.

Authors:  A J Salsbury; K Burrage; K Hellmann
Journal:  Br Med J       Date:  1970-11-07

6.  Effect of Triton WR 1339 on cancer dissemination and metastases.

Authors:  R Rosso; M G Donelli; G Franchi; S Garattini
Journal:  Eur J Cancer       Date:  1969-02       Impact factor: 9.162

7.  Triton WR 1339 (TWR), an inhibitor of cancer dissemination and metastases.

Authors:  G Franchi; L Morasca; S Garattini
Journal:  Eur J Cancer       Date:  1971-12       Impact factor: 9.162

8.  Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action.

Authors:  A W Le Serve; K Hellmann
Journal:  Br Med J       Date:  1972-03-04

9.  Preliminary clinical assessment of I.C.R.F. 159 in acute leukaemia and lymphosarcoma.

Authors:  K Hellmann; K A Newton; D N Whitmore; I W Hanham; J V Bond
Journal:  Br Med J       Date:  1969-03-29

10.  Use of first generation transplants of a slow growing solid tumor for the evaluation of new cancer chemotherapeutic agents.

Authors:  J Sandberg; A Goldin
Journal:  Cancer Chemother Rep       Date:  1971-06
View more
  2 in total

1.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.

Authors:  I W Taylor; N M Bleehen
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.